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Medullary thyroid carcinoma (MTC) is a tumor derived from the parafollicular C cells; it
represents 3% to 10% of thyroid gland malignancies, but it is responsible for up to 13.4% of
deaths that are caused by thyroid cancer (1). The proportion of medullary thyroid cancer to thy-
roid malignancies does not show a significant variation in geography, or regional iodine status.
MTC may occur in sporadic (70-84%) and familial forms (16-30%), inherited as an autosomal
dominant pattern of transmission (2, 3). All ages may be affected by this neoplasm, but its inci-
dence peaks during the fourth and sixth decaded of life for the sporadic type and the second and
third for the familial type (3). There is a slow increase in incidence with age and a slight female
predominance among whites. Table 1 summarized the main features of the various types of
MTC.
Pathology
Medullary thyroid carcinoma develops in C cells. The C cells have great byosynthetic activity
and secrete several hormones and biogenic amines, including calcitonin (CT), ACTH, histamina-
se, carcinoembryogenic antigen (CEA). Clinically, the most important of these is CT, a peptide
hormone, composed of 32 amino acids, which serves as an excellent tumor marker for MTC. The
C cells are embryologically derived from the neural crest and are unrelated to the thyroid follicu-
lar cells. These cells and MTC become distributed typically within the middle and upper third of
the lateral thyroid lobes.
MTC is usually solid, firm, non-encapsulated, but relatively well circumscribed and either whi-
tish or red in colour. On histological examination, it consists in clusters of spindle-shaped, poly-
gonal or round cells separated by fibrous stroma. The nuclei are usually uniform in shape with
rare mitotic figures. Amyloid is frequently present. In all MTCs there is positive immunohisto-
chemical staining for CT and CEA.
C cell hyperplasia (CCH) is a histologic abnormality associated and even implicated as the pre-
cursor of the hereditary types of MTC. CCH is present in all patients with hereditary MTC.
Familial MTCs derived form CCH are bilateral, multicentric neoplasms. In contrast, sporadic
MTCs are usually unifocal. MTC is usually considered an indolent disease, with prolonged survi-
val, although it spreads early in its course to regional lymph nodes. Palpable MTC is reported to
present with cervical lymph node metastases in 25-82% of cases; they are correlated with the size
of the intrathyroid primary tumour (4, 5).
Clinical presentation and diagnosis
The most common presentation of MTC is a painless thyroid nodule. Less commonly, the
patient may present pain, dysphagia, hoarseness, or diarrhea. At initial presentation, the thyroid
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swelling may be associated in up to 75% of patients with cervical lymphadenopathy which may
not always be palpable.
Another mode of presentation is the patient who is found to have MTC on screening for
medullary carcinoma as a component of MEN that presents with another neoplasm, or a family
member of a patient with MEN.
The cornerstone to the diagnosis of MTC is the measurement of plasma calcitonin levels,
representing the most sensitive diagnostic test. Virtually all patients with MTC have elevated basal
calcitonin. It can be exploited for screening, diagnosis, and follow-up of the disease. The routine
basal calcitonin measurement allows the identification of MTC at a preclinic stage; provocative
test (pentagastin and/or calcium) are accurate to differentiate between MTC-related hypercalci-
toninemia from non thyroidal disease (ectopic secretion, renal insufficiency) (6).
Ultrasonography is a rapid, easy, noninvasive tool; it typically reveals a hypoechogenic solid
nodule, and the state of the neck adenopathy. Ultrasonography can also guide fine needle aspira-
tion cytology (FNAC). FNAC is adequate and easy, but it makes the correct diagnosis of MTC
in only 50% of the cases and it is less sensitive than CT measurements (6).
The usual cytological findings for MTC are polygonal or triangular cells that are commonly
binucleated with eccentric nuclei containing a coarse, granular chromatin pattern. The cytoplasm
is abundant or moderate in amount with fine granularity and azurophylic granules. In addition,
amyloid is found in variable amounts in the amorphous substance.
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TABLE 1 - MAIN FEATURES OF SPORADIC AND HEREDITARY MTC.
Sporadic MTC associated MTC associated Isolated familial 
MTC to MEN 2A to MEN 2B MTC
Incidence 70% 20% 5% 5%
F:M ratio >1 =1 =1 =1
Age at diagnosis >45 years 20-30 years 1-10 years Variable
Hystopathologic Unilateral lesion Multifocal Multifocal Multifocal
features Absence of C and bilateral lesions and bilateral lesions and bilateral lesions
cell hyperplasia Presence of C Presence of C Presence of C
cell hyperplasia cell hyperplasia cell hyperplasia
Associated - Pheochromocytoma Pheochromocytoma -
diseases (20-80%) (20-60%)
Hyperparathyroidism Marphanoid features
(10-30%) (80-90%)
Genetic RET somatic mutations RET RET RET
marker germinal mutations germinal mutations germinal mutations
(exons 10,11) (exon 16) (exons 10,11,13,14,15)
Surgical Total thyroidectomy Total thyroidectomy Total thyroidectomy Total thyroidectomy
treatment + + + +
Central node dissection Central node dissection Central node dissection Central node dissection
+ + + +
Mono or bilateral Bilateral Bilateral Bilateral
neck dissection neck dissection neck dissection neck dissection
Prophylactic None Total thyroidectomy Total thyroidectomy Total thyroidectomy
treatment (5 years) (1 - 6 months) (according to the 
(age) type of mutation)
Furthemore, a CT scan that included the whole neck and mediastinum is required before sur-
gery. The use of various scintigraphic studies is reserved for recurrence or metastatic disease.
MTC and MEN syndromes
Hereditary MTC is transmitted as an autosomal dominant trait; it may be inherited alone
(Familial Medullary Thyroid Carcinoma, FMTC) or as part of a Multiple Endocrine Neoplasia
(MEN) 2A or 2B syndrome. Germ-line mutation of the RET proto-oncogene were identified in
MEN 2A, FMTC and MEN 2B. The gene has 21 exons and it is located on chromosome 10q11.2;
it encodes a tyrosine-kinase receptor. Patients with MEN 2A or 2B syndromes are primarily cha-
racterized by the occurrence of multifocal MTC and pheochromocytoma which is bilateral in
40% to 50% of cases. In addition, patients with MEN 2A may develop primary hyperparathy-
roidism, cutaneous lichen amyloidosis and Hirschsprung’s disease (7).
Patients with MEN 2B syndrome are usually affected at a younger age with more aggressive
tumours. In addition, these patients have a marfanoid habitus and develop mucosal gangliomas
in the gastrointestinal tract, conjunctiva, tongue, and lips. The RET proto-oncogene encodes a
cell surface tyrosine-kinase receptor with a large extracellular domain, a transmembrane domain
and two cytoplasmic tyrosine-kinase domains. Germ-line mutations in different codons of this
gene result in different phenotypes of the disease (8).
Mutations causing MEN 2A affect the cysteine-rich extracellular domain. These mutation are
located in codon 634 (exon 11) or codons 609/611/618 and 620 (exon 10). The most common
mutation, accounting for over 80% of all mutations associated with MEN 2A, affect the codon
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TABLE 2 - CORRELATION BETWEEN GENOTYPE AND PHENOTYPE AND THERAPEUTIC IMPLICA-
TIONS IN MTC.
Risk category Mutations Phenotype Age for
prophylactic surgery
Highest risk exon 16 (codon 918) MEN 2B first 1- 6 months
High risk exon 11 (codon 634) MEN 2A, FMTC 5 years
exon 10 (codons 609, 611, (possibly later 
618 and 620) for 609 mutations)
Intermediate exon 13 (codon 768, 790, 791)
risk exon 14 (codon 804, 844) FMTC 5-10 years or later
exon 15 (codon 891)
Fig. 1 - Right modified lateral neck dissection for MTC (lateral
vision). 1: omohyoid muscle (sectioned); 2: ansa cervicalis; 3: jugu-
lar vein; 4: vagus nerve; 5: carotid artery; 6: accessory spinal
nerve; 7: cervico-brachial plexus.
634. In about half of FMTC kindreds mutations affect codons in exon 10 (mainly 618, 620);
mutations affecting exons 11, 13, 14 and 15 occur more rarely. The main mutation in patients with
MEN 2B is at codon 918 (exon 16) which encodes part of the cytoplasmatic tyrosine-kinase
catalytic domain of the receptor (9).
Screening for MTC by testing for genetic mutations can also predict the occurrence of the
disease, which allows for earlier surgery and potentially relieves the patient from worrying about
the routine check-up. Approximately 5% of patients with apparently sporadic MTC have a germ-
line mutation of the RET gene, and consequently hereditary MTC. A blood RET proto-oncoge-
ne analysis is advocated for all patients with apparently sporadic MTC. All patients with a germ-
line RET mutation should undergo a prophylactic total thyroidectomy, though the timing of sur-
gery is controversial.
Recently, according to the type of mutation, patients with hereditary MTC have  been divided
into three different risk categories (Table 2) (10). Patients with 918 mutations (MEN2B) should
be operated early (at the first month of life), because of the aggressiveness of the disease, while
patients with mutations in exons 13, 14 or 15 could undergo prophylactic surgery later, up to the
third or even fourth decade of life (11) or, alternatively, when pentagastrin stimulation test beco-
mes abnormal.
Treatment
The primary treatment of MTC is the surgical removal of all neoplastic tissue present in the
neck, and should be performed after careful exclusion of a pheochromocytoma by biochemical
studies (urinary catecholamines, urinary and plasmatic metanephrines). In fact, in case of MEN,
adrenalectomy should be performed prior to thyroidectomy, to avoid the possible hazardous
effects of hormonally-active pheochromocytoma during neck surgery.
Several studies have shown that survival in patients with MTC is dependent upon the ade-
quacy of the initial surgical procedure. For several reasons total thyroidectomy and systematic
central neck node dissection is indicated for both the hereditary and sporadic forms. Familial
MTC is almost always multifocal and bilateral; 30% of sporadic cases have bilateral disease,
approximately 5% of apparently sporadic MTC prove to be index cases for hereditary forms;
finally, in all cases nodal spreading occur very early.
Some authors recommend inclusion of the lateral neck dissection only if central or lateral
lymph node metastases are proved, or if the primary tumor is palpable. In fact nodal metastases
usually increase according to the size of the tumor, although large MTC without nodal involve-
ment have been published (7). Others recommend systematic lateral modified neck lymph node
dissection (Fig. 1), based on the notoriously high incidence of regional lymphatic involvement.
Contralateral lymph node dissection may be omitted only in patients with an unilateral thyroid
tumour and with no ipsilateral and central lymph node involvement. If mediastinal lymph node
metastases are proved, this compartment should be dissected systematically.
In young gene carriers, detected through family screening, with normal basal or pentagastrin-
stimulated calcitonin level and no overt thyroid lesion, total thyroidectomy results to be prophy-
lactic and, subsequently, curative.
All parathyroid glands should be identified during thyroidectomy, however controversy exists
regarding how these glands should be preserved to maintain function. Some authors preserve the
superior parathyroids in situ, since inferior glands are usually excised at the time of central node
dissection; others perform total parathyroidectomy with autotransplantation (12). An invasive
medullary carcinoma may require resection of a part or a sleeve of the trachea or a part of the
pharyngeal wall.
Following surgical treatment, the patients are monitored with regular measurements of basal
and pentagastrin-stimulated serum calcitonin levels. Calcitonin and CEA levels should usually be
assessed for baseline levels approximately 4 weeks after surgery (13). A persistent or re-elevating
level may indicate loco-regional recurrence or metastatic disease.
In patients with persistently elevated CT levels, the challenge is finding the site of residual
disease. Tumour localization techniques include ultrasonography of the neck and liver, CT or
MRI of the neck, chest and liver, and bone scintigraphy. Isotopic scanning with thallium 201,
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dimercaptosuccinic acid labelled with 99mTc, 123-I metaiodobenzyl-guanidine (MIBG), soma-
stotatin analogues labelled with indium 111 or monoclonal antibiodes directed against CT or
CEA, and even position emission tomography (PET) with FDG are poorly sensitive. Liver meta-
stases may be difficult to visualize by these imaging modalities and may be identified only at lapa-
roscopy.
Selective venous sampling catheterization with CT measurements appears to be the most sen-
sitive and specific technique for localizing occult metastatic disease.
Patients with elevated calcitonin should be carefully selected for reoperation. Iterative surgery
is rarely curative in case of recurrent or persistent MTC, and should be reserved only for cases
localized exclusively at the neck. Reoperations could be effective in reducing calcitonin levels, but
the real impact on survival is being debated.
Although there are ongoing clinical trials, no single agent or combination chemotherapy has
been shown to be beneficial in the control of metastatic disease. Future directions include the use
of gene therapy, for inactivation or destruction of RET, and 131-I MIBG fot the treatment of
advanced and metastatic disease.
Abstract
Medullary thyroid carcinoma (MTC) constitutes about 3-10% of all thyroid cancers. It arises from the parafollicular C
cells that produce calcitonin (CT) and occurs as a sporadic form. or less commonly, as a hereditary form, as part of mul-
tiple endocrine neoplasia syndromes types 2A (MEN 2A) and 2B (MEN 2B). The hereditary forms are autosomal domi-
nant traits associated with germline mutations of RET proto-oncogene. Progresses in genetics have permitted an impro-
vement of management, screening and treatment. Surgery is the only successful treatment for MTC, as there is no effec-
tive adjuvant therapy for residual disease. A total thyroidectomy and vigilant management and surveillance of the neck
are recommended. Interdisciplinary management including surgeons, endocrinologists, pathologists, radiotherapists,
radiologists, and oncologists should be considered.
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